Why Moodgaine Exists
Moodgaine exists to provide clear, evidence‑first information about ibogaine specifically for people living with depression and those supporting them. Our mission is to gather, summarize, and explain research findings, regulatory context, safety screening practices, and realistic expectations so that readers can make informed decisions without marketing hype.
We are intentionally independent: we are not a clinic, medical provider, or licensed treatment center. That independence shapes our editorial approach and our willingness to highlight uncertainty, gaps in the evidence, and safety priorities rather than promoting treatments or services.
The guiding principle is plainspoken evidence: describe what is known, what is unknown, and what practical precautions people should consider.
Our editorial approach
We assemble content by surveying peer‑reviewed studies, preprints, clinical registries, regulatory announcements, and reputable summaries from academic and government sources. When we make a factual claim about safety screening, mechanisms, or trial results, we anchor that claim to primary sources such as clinical trial reports or regulator statements and to trusted reference sites like Wikipedia for foundational definitions where helpful.
For example, when we discuss study signals or trial designs we consult primary trial reports and institutional summaries rather than promotional materials, and we cross-check regulatory status with official agency pages and recognized academic centers.
What we cover
Content on Moodgaine is organized thematically: concise evidence summaries, safety & screening guidance for lay readers, explanatory primers on trial design and regulatory status, and accessible Q&A for families and care partners. We prioritize content that directly addresses the needs and decisions of people living with depression.
We also maintain an index of topical pages such as our services overview and a plain‑language evidence hub; those sections are signposted from the site menu and cross‑linked in contextual prose to help readers navigate.
To return to the site’s homepage and the curated entry points for newcomers, follow the editorial gateway that explains scope and recent updates on the main page at the site root (we link readers back to the primary overview at the Moodgaine overview).
How information is sourced and vetted
We use a combination of primary literature review, clinical trial registries, regulator press releases, and institutional communications from recognized academic centers to vet claims. When available, we link to peer‑reviewed trials and to authoritative institutional summaries so readers can inspect original texts. For foundational context (definitions, regulatory terms), we cite reputable references such as the Encyclopaedia‑style entry on ibogaine on Wikipedia and official agency pages when discussing approvals or trial design nuances.
Our sourcing practices also include cross‑checking provider statements against independent surveys and clinic overviews; for instance, independent catalogues of retreat marketing claims are reviewed to contrast promotional language with peer‑reviewed findings (an independent survey of retreat marketing provides one such example).
Editorial principles
- Independence: No clinic affiliations or treatment promotions; we publish without commercial influence.
- Plain language: Scientific findings translated into practical terms for people living with depression.
- Evidence‑forward: Distinguish between anecdote, open‑label signals, and randomized evidence.
- Safety first: Emphasize screening and monitoring requirements where treatments exist.
- Audience centered: Content tailored to patients and care partners, not clinicians or marketers.
Who this is for
Moodgaine is written for people living with depression and for family members, friends, and clinical supporters trying to assess experimental options. If you are exploring treatment choices, our pages synthesize study signals, highlight safety screening measures, and explain regulatory contexts so you can discuss options knowledgeably with licensed clinicians.
We also provide editorial context on service landscapes and directories of published evidence; for a sense of how clinics represent services and outcomes, readers can review independent overviews that survey retreat claims across regions such as Europe and Mexico (ibogaine treatment in Europe and retreats in Mexico).
Independent by design
We repeat the important disclosure plainly: Moodgaine is an independent information resource. We are not a clinic, medical provider, or licensed treatment center, and nothing on this site should be interpreted as medical or legal advice. Readers should consult a licensed clinician for individual medical guidance and verify clinic screening standards and monitoring practices when evaluating care options.
If you'd like a focused summary of evidence or safety pages, our Services section outlines the types of content and summaries we publish (services and editorial offerings).
Authoritative sources we consult
To support our editorial standards we frequently consult institutional pages and academic repositories such as the U.S. National Library of Medicine and university press summaries; these sources help ground statements about trial design and safety screening (National Library of Medicine is one example of a registry we consult).